Armata Pharmaceuticals (ARMP) Q2 2024 earnings summary

Executive summary

• Focused on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections, with two lead candidates in late-stage clinical trials targeting chronic and acute infections.

• Completed enrollment and last patient visit in the Phase 2 Tailwind study for non-cystic fibrosis bronchiectasis; topline data expected in the second half of 2024.

• Advanced Phase 2a diSArm study for S. aureus bacteremia, with over 60% enrollment and $5.25M–$21.6M in non-dilutive grant funding.

• Completed build-out of advanced cGMP manufacturing facility to support late-stage trials and potential commercial production.

Financial highlights

• Net income of $9.0 million for Q2 2024, compared to a net loss of $3.5 million in Q2 2023, driven by a $23.4 million gain from change in fair value of convertible debt.

• Net loss for Q2 2024 was $8.99 million, with a basic EPS of $0.25 and diluted EPS of $(0.25); net loss for the six months ended June 30, 2024, was $16.0 million.

• Cash and cash equivalents of $26.4 million as of June 30, 2024, up from $13.5 million at year-end 2023.

• Operating expenses increased 12.3% year-over-year for Q2, mainly due to higher general and administrative costs; R&D expenses for Q2 2024 were $8.5 million, up 2.6% year-over-year.

Outlook and guidance

• Current cash is insufficient to fund operations for the next 12 months; substantial doubt exists about ability to continue as a going concern without additional capital.

• Plans to raise additional capital through equity, debt, or strategic arrangements; future funding needs depend on R&D, clinical progress, and regulatory milestones.

• Topline data from the Tailwind Phase 2 study expected in H2 2024, with potential pivotal trial initiation in 2025.

• Completion of the diSArm Phase 2a study and dose selection for AP-SA02 anticipated later in 2024.